Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04331743 | A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jun 16, 2021 | clinicaltrials |
| NCT03423992 | Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas | unknown | Phase 1 | 100 | Xuanwu Hospital, BeijingOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04926532 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma(Toripalimab) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04897477 | Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04162340 | CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies | unknown | Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04888442 | Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | unknown | Phase 1 | 18 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | May 17, 2021 | clinicaltrials |
| NCT04886765 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | unknown | Phase 1 / Phase 2 | 238 | AlaMab Therapeutics (Shanghai) Inc.INDUSTRY | 0 | May 14, 2021 | clinicaltrials |
| NCT04887012 | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04289220 | Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04884984 | Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04873440 | An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03925285 | Image Guided Surgery in Sinonasal Inverted Papilloma(SNIPER) | unknown | Phase 1 | 6 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03620292 | Fluorescence Image Guided Surgery in Cholangiocarcinoma(COUGAR) | unknown | Phase 1 / Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03754179 | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma(COMBI-R2) | unknown | Phase 1 / Phase 2 | 63 | Universitair Ziekenhuis BrusselOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04854681 | Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers | unknown | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 0 | Apr 22, 2021 | clinicaltrials |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | unknown | Phase 1 / Phase 2 | 26 | David Minor, MDOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04843943 | Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Apr 14, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT01976520 | Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 1 | 30 | XEME Biopharma Inc.INDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04796675 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | unknown | Phase 1 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04412577 | A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies | unknown | Phase 1 | 57 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04814004 | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors | unknown | Phase 1 | 20 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT04653493 | CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | unknown | Phase 1 | 22 | Sabz BiomedicalsINDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04691765 | Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients(Anakinra) | unknown | Phase 1 | 12 | Dr. David SpanerOTHER | 0 | Mar 19, 2021 | clinicaltrials |
| NCT04806659 | A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia | unknown | Phase 1 | 41 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796688 | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT04790747 | Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | unknown | Phase 1 | 42 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04121273 | GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | unknown | Phase 1 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04170595 | Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection | unknown | Phase 1 / Phase 2 | 132 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04594135 | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies(CD5CAR-T) | unknown | Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04003168 | Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04772846 | Chloroquine for Glioblastoma. | unknown | Phase 1 / Phase 2 | 60 | Egyptian Medical SyndicateOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04766840 | Donor-derived CAR-T Cells in the Treatment of AML Patients | unknown | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jun 16, 2021source: clinicaltrials